Advertisement
U.S. markets open in 1 hour 58 minutes

Genfit S.A. (GNFT)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
3.5200+0.0600 (+1.73%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.4600
Open3.5100
Bid3.4000 x 1000
Ask4.1800 x 900
Day's Range3.5100 - 3.5200
52 Week Range2.8940 - 4.7500
Volume1,988
Avg. Volume19,628
Market Cap175.419M
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-0.8000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GNFT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GENFIT S.A.
    Daily – Vickers Top Buyers & Sellers for 03/06/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    13 days agoArgus Research
View more
  • GlobeNewswire

    GENFIT Announces Revenues and Cash Position as of December 31, 2023

    Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 million Upcoming FDA PDUFA action date for elafibranor in PBC: June 10, 2024 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liv

  • GlobeNewswire

    GENFIT Announces 2024 Financial Calendar

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2024. 2024 Financial Calendar February 29, 2024 Publication of revenue and cash position at December 31, 2023 April 4, 2024 Publication of Full Year 2023 financial statements The

  • GlobeNewswire

    GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 11, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity accoun